

Report of *in vitro* antileishmanial properties of Iberian macroalgae

Carolina Bruno de Sousa¹, João Henrique G. Lago², Jorge Macridachis¹, Marta Oliveira^{1,3}, Luis Brito¹, Catarina Vizetto-Duarte¹, Cláudia Florindo^{4,5}, Sarah Hendrickx⁶, Louis Maes⁶, Thiago Morais², Miriam Uemi², Luís Neto⁷, Lúdia Dionísio⁷, Sofia Cortes³, Luísa Barreira¹, Luísa Custódio¹, Fernando Alberício⁸, Lenea Campino³ and João Varela^{1*}

¹ Centre of Marine Sciences, University of Algarve, Campus de Gambelas, 8005-139 Faro, Portugal.

² Instituto de Ciências Ambientais, Químicas e Farmacêuticas, Universidade Federal de São Paulo, São Paulo 09972-270, Brazil.

³ Global Health and Tropical Medicine Centre, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, 1349-008 Lisboa, Portugal.

⁴ Programa de Medicina Regenerativa, Departamento de Ciências Biomédicas e Medicina, UAlg, 8005-139 Faro, Portugal.

⁵ Centro de Investigação Biomédica, University of Algarve, 8005-139 Faro, Portugal.

⁶ Department of Biomedical Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Antwerp University, Antwerp, Belgium.

⁷ Faculdade de Ciências e Tecnologia, University of Algarve, Faro, Portugal.

⁸ Institute for Research in Biomedicine, Barcelona Science Park, Barcelona, Spain.

* Corresponding author. Email: jvarela@ualg.pt

Acknowledgments

This work was supported by the Foundation for Science and Technology (FCT) and the Portuguese National Budget under the grants PTDC/MAR/103957/2008 and CCMAR/Multi/04326, GHTM-UID/Multi/04413/2013 projects; SFRH/BD/78062/2011, SFRH/BD/81425/2011, IF/00049/2012 and IF/00743/2015 grants; and the Brazilian institutions, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).

Report of *in vitro* antileishmanial properties of Iberian macroalgae

Abstract

Here is reported the anti *Leishmania infantum* activity of 45 hexane, dichloromethane and ethanol extracts from 16 macroalgae collected on the Iberian Coast. Seven hexane and dichloromethane *Cystoseira baccata*, *C. barbata*, *C. tamariscifolia*, *C. usneoides*, *Dictyota spiralis* and *Plocamium cartilagineum* extracts were active towards promastigotes (IC₅₀ 29.8-101.8 µg/mL) inducing strong morphological alterations in the parasites. Hexane extracts of *C. baccata* and *C. barbata* were also active against intracellular amastigotes (IC₅₀ 5.1 and 6.8 µg/mL, respectively). Fatty acids, triacylglycerols, carotenoids, steroids, and meroterpenoids were detected by nuclear magnetic resonance (NMR), and gas chromatography (GC) in the *Cystoseira* extracts. These results suggest that *Cystoseira* macroalgae contain compounds with antileishmanial activity, which could be explored as scaffolds to the development of novel sources of antiparasitic derivatives.

Keywords: Antiparasitic, *Leishmania infantum*; Leishmaniasis; Macroalgae; *Cystoseira*; Secondary metabolites.

1. Introduction

Leishmaniasis are vector-borne diseases caused by *Leishmania* parasites, and transmitted by phlebotomine sand flies, which affect more than 12 million people in 98 countries (Alvar et al. 2012). Drugs available for controlling leishmaniasis have serious side effects and limited effectiveness due to growing parasite resistance. In this context, the development of novel drugs is of paramount importance (Sundar & Chakravarty 2015). Marine resources are recognized as rich sources of compounds for the biodiscovery of novel drug leads which could also be used for antileishmanial therapy and control (Tempone et al. 2011). Several macroalgae species show to be toxic to *Leishmania* parasites however few publications described the identification of promising molecules for future studies regarding leishmaniasis treatment (Yamthe et al., 2017). This study evaluated the *in vitro* activity of hexane (HEX), dichloromethane (DCM) and methanolic (MeOH) extracts of 16 macroalgae species from the Iberian coast against *L. infantum*, the species responsible for the canine leishmaniasis and the most severe form of human disease, the visceral leishmaniasis. Results suggested that *Cystoseira* contain compounds with antileishmanial activity.

2. Results and discussion

Screening of 16 macroalgae extracts using the MTT colorimetric assay enabled the detection of activity against *L. infantum* promastigotes in six species (Tables S1 and S2). Most of the identified bioactive extracts that decreased promastigote viability by 50% at concentrations lower than 94 µg/mL belonged to *Cystoseira* species, effects similar to those obtained for crude extracts of other algae of the same phylum (Yamthe et al., 2017). Although axenic promastigotes are often used for the *in vitro* preliminary drug screening, promising products should be evaluated on the clinical relevant stage in the vertebrate host, the intracellular amastigotes (Tempone et al. 2011). *C. tamariscifolia* and *C. usneoides* HEX and DCM extracts were the most active (IC₅₀ 29.8 - 33.6 µg/mL) against promastigote forms. However, its high toxicity against THP-1 mammalian cells prevented its evaluation upon the intracellular model (Figure 1). Conversely, *C. baccata* and *C. barbata* HEX extracts that decreased by half the promastigote viability at 94.1 and 78.7 µg/mL presented good selectivity when assayed against the intracellular model. Incubation with the aforementioned extracts decreased infection by 50% at 5.1 and 6.8 µg/mL, respectively, with cytotoxicity similar to that of the reference drug miltefosine (Figure 1; Table S2). These results showed that the *C. baccata* and *C. barbata* HEX extracts displayed higher leishmanicidal activity than those described for other *Cystoseira* against axenic (IC₅₀ > 23.5 µg/mL; Süzgeç-Selçuk et al. 2010) and intracellular (IC₅₀ > 15.7 µg/mL; Spavieri et al. 2010) *L. donovani* amastigotes.

The effect of *Cystoseira* extracts on promastigotes was also analysed by optical microscopy, revealing the occurrence of morphological changes (Figure S1) similar to those observed after treatment of *Leishmania* promastigotes with extracts from marine sponges (Kahla-Nakbi et al., 2010). Extracts induced motility loss, cell shrinkage, abnormal round cell shapes, vacuolated and slightly denser cytoplasm as well as reduction of flagellar length in parasite cells (Figure S1D). Loss of motility and cellular vacuolization could be consequence of starvation processes caused by a deficient mitochondrial activity, autophagic mechanisms or cytoplasmic organelle disruption (Lockshin & Zakeri 2004; Monte Neto et al., 2011). These results together with the absence of phosphatidylserine externalization, observed in promastigotes treated with the extracts for 48h (data not shown), suggest that crucial organelles, such as mitochondria, are compromised and that the observed leishmanicidal effect might not be associated with programmed cell death.

Chemical profiles of the active *Cystoseira* extracts investigated using different analytical methods (NMR, GC/FID and GC/LREIMS) reveal the occurrence of different classes of

metabolites (Table S3; Figures S2 and S3) in agreement with previous studies focusing on *Cystoseira* (Bruno de Sousa, et al. 2017a). Unsaturated fatty acids such as arachidonic and eicosapentaenoic (EPA) acids were found in the HEX extracts. EPA was found to be effective against *L. donovani* promastigotes (Vassallo et al. 2011) and triacylglycerols against *L. aethiopica* (Bekele et al. 2013) and *L. amazonensis* (Rodrigues et al. 2014). Steroids such as cholesterol, sitosterol, stigmasterol and fucosterol, also identified in all the analysed HEX extracts. The antileishmanial effect of fucosterol and sitosterol isolated from other biological sources has already been reported (Bruno de Sousa et al., 2017b). Concerning meroterpenoids, E- and Z-usnoidones were identified in the *Cystoseira* studied extracts. Other meroterpenoids were also detected in bioactive CH₂Cl₂ extracts, except from *C. tamariscifolia*. Meroterpenoids have already been described as having several bioactive properties (Reyes et al. 2013) including antileishmanial (Bruno de Sousa et al. 2017a). Although their effect on *Leishmania* has been associated with the inhibition of adenosine phosphoribosyltransferase (Gray et al. 2006), their antileishmanial activity remains poorly studied.

3. Conclusions

Our results suggest that *Cystoseira* are a source of metabolites with activity against *L. infantum*. In that context, further bioguided fractionation of the active *Cystoseira* extracts should be carried out in order to identify the active components.

Disclosure statement

No potential conflict of interest was reported by the authors.

References

- Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Janni J, Boer MD. 2012. Leishmaniasis worldwide and global estimates of its incidence. *PLoS One*. 7:e35671.
- Bekele B, Adane L, Tariku Y, Hailu A. 2013. Evaluation of antileishmanial activities of triglycerides isolated from roots of *Moringa stenopetala*. *Med. Chem. Res.* 22:4592-4599.
- Bruno de Sousa C, Gangadhar KN, Macridachis J, Pavão M, Morais TR, Campino L, Varela J, Lago JHG. 2017b. *Cystoseira* Algae (Fucaceae): Update on their Chemical Entities and Biological Activities. *Tetrahedron: Asymmetry*. <https://doi.org/10.1016/j.tetasy.2017.10.014>

122 Bruno de Sousa C, Gangadhar KN, Morais TR, Conserva GA, Vizetto-Duarte C, Pereira H, Laurenti
 123 MD, Campino L, Levy D, Uemi M, Barreira L, Custódio L, Passero LF, Lago JH, Varela J. 2017a.
 124 Antileishmanial activity of meroditerpenoids from the macroalgae *C. baccata*. *Exp. Parasitol.* 174:1-9.
 125 Gray CA, de Lira SP, Silva M, Pimenta EF, Thiemann OH, Oliva G, Hajdu E, Andersen RJ, Berlinck
 126 RGS. 2006. Sulfated meroterpenoids from the Brazilian sponge *Callyspongia* sp. are inhibitors of the
 127 antileishmaniasis target adenosine phosphoribosyltransferase. *J. Org. Chem.* 71:8685-8690.
 128 Kahla-Nakbi A, Haouas N, Ouaer AE, Guerbej H, Mustapha KB, Babba H. 2010. Screening of
 129 antileishmanial activity from marine sponge extracts collected off the Tunisian coast. *Parasitol. Res.*
 130 106:1281-1286.
 131 Lockshin RA, Zakeri Z. 2004. Apoptosis, autophagy, and more. *Int J Biochem Cell Biol* 36:2405-19.
 132 Monte Neto RL, Sousa LMA, Dias CS, Barbosa Filho JM, Oliveira MR, Figueiredo RCBQ. 2011.
 133 Morphological and physiological changes in *Leishmania* promastigotes induced by yangambin, a
 134 lignan obtained from *Ocotea duckei*. *Exp. Parasitol.* 127:215-221.
 135 Reyes C, Zbakh H, Motilva V, Zubía E. 2013. Antioxidant and anti-inflammatory meroterpenoids
 136 from the brown alga *Cystoseira usneoides*. *J. Nat. Prod.* 76:621-629.
 137 Rodrigues A, Farias L, Carvalho A, Santos A, Nascimento J, Silva E. 2014. A novel function for Kojic
 138 acid, a secondary metabolite from *Aspergillus* fungi, as antileishmanial agent. *PLoS One.* 9:e91259.
 139 Spavieri J, Allmendinger A, Kaiser M, Casey R, Hingley-Wilson S, Lalvani A, Guiry MD, Blunden G,
 140 Tasdemir D. 2010. Antimycobacterial, antiprotozoal and cytotoxic potential of twenty-one brown
 141 algae (Phaeophyceae) from British and Irish waters. *Phytother. Res.* 24:1724-1729.
 142 Sundar S, Chakravarty J. 2015. Investigational drugs for visceral leishmaniasis. *Expert Opin. Investig.*
 143 *Drugs.* 20:43-59.
 144 Süzgeç-Selçuk S, Meriçli AH, Güven KC, Casey R, Hingley-Wilson S, Lalvani A, Guiry MD,
 145 Blunden G, Tasdemir D. 2010. Evaluation of Turkish seaweeds for antiprotozoal, antimycobacterial
 146 and cytotoxic activities. *Phytother. Res.* 25:778-783.
 147 Tempone AG, Martins de Oliveira C, Berlinck RG. 2011. Current approaches to discover marine
 148 antileishmanial natural products. *Planta Medica.* 77:572-585.
 149 Vassallo O, Castelli S, Biswas A, Sengupta S, Das PK, D'Annessa I, Oteri F, Leoni A, Tagliatesta P,
 150 Majumder HK, Desideri A. 2011. Conjugated eicosapentaenoic acid (cEPA) inhibits *L. donovani*
 151 topoisomerase I and has an antiproliferative activity against *L. donovani* promastigotes. *Open*
 152 *Antimicrob. Ag. J.* 3:23-29.
 153 Yamthe LR, Appiah-Opong R, Fokou PVT, Tsabang N, Boyom FF, Nyarko AK, Wilson MD.
 154 2017 Marine algae as source of novel antileishmanial drugs: A review. *Mar. Drugs.* 15:323

155 **FIGURE CAPTIONS**

156 **Figure 1.** Effect of the *L. infantum* and mammalian cells treatment with *Cystoseira* spp.
157 active hexane extracts and the reference drug Miltefosine. Significant differences between
158 extracts and reference drug are indicated as *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$ (Student's
159 t-test).

1 SUPPLEMENTARY MATERIAL

2

3 Report of *in vitro* antileishmanial properties of Iberian macroalgae

4

5 Carolina Bruno de Sousa¹, João Henrique G. Lago², Jorge Macridachis¹, Marta
6 Oliveira^{1,3}, Luis Brito¹, Catarina Vizetto-Duarte¹, Cláudia Florindo^{4,5}, Sarah
7 Hendrickx⁶, Louis Maes⁶, Thiago Moraes², Miriam Uemi², Luís Neto⁷, Lúdia
8 Dionísio⁷, Sofia Cortes³, Luísa Barreira¹, Luísa Custódio¹, Fernando Alberício⁸,
9 Lenea Campino³ and João Varela^{1*}

10

11¹ Centre of Marine Sciences, University of Algarve, Campus de Gambelas, 8005-139 Faro, Portugal.

12² Instituto de Ciências Ambientais, Químicas e Farmacêuticas, Universidade Federal de São Paulo, São
13 Paulo 09972-270, Brazil.

14³ Global Health and Tropical Medicine Centre, Instituto de Higiene e Medicina Tropical, Universidade
15 Nova de Lisboa, 1349-008 Lisboa, Portugal.

16⁴ Programa de Medicina Regenerativa, Departamento de Ciências Biomédicas e Medicina, UAlg, 8005-
17 139 Faro, Portugal.

18⁵ Centro de Investigação Biomédica, University of Algarve, 8005-139 Faro, Portugal.

19⁶ Department of Biomedical Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences,
20 Antwerp University, Antwerp, Belgium.

21⁷ Faculdade de Ciências e Tecnologia, University of Algarve, Faro, Portugal.

22⁸ Institute for Research in Biomedicine, Barcelona Science Park, Barcelona, Spain.

23

24* Corresponding author. Email: jvarela@ualg.pt

25Abstract

26Here is reported the anti *Leishmania infantum* activity of 45 hexane, dichloromethane and
27ethanol extracts from 16 macroalgae collected on the Iberian Coast. Seven hexane and
28dichloromethane *Cystoseira baccata*, *C.barbata*, *C. tamariscifolia*, *C. usneoides*, *Dictyota*
29*spiralis* and *Plocamium cartilagineum* extracts were active towards promastigotes (IC₅₀ 29.8-
30101.8 µg/mL) inducing strong morphological alterations in the parasites. Hexane extracts of *C.*
31*baccata* and *C. barbata* were also active against intracellular amastigotes (IC₅₀ 5.1 and 6.8
32µg/mL, respectively). Fatty acids, triacylglycerols, carotenoids, steroids, and meroterpenoids
33were detected by nuclear magnetic resonance (NMR), and gas chromatography (GC) in the
34*Cystoseira* extracts. These results suggest that *Cystoseira* macroalgae contain compounds with
35antileishmanial activity, which could be explored as scaffolds to the development of novel
36sources of antiparasitic derivatives.

37**Keywords:** Antiparasitic, *Leishmania infantum*; Leishmaniasis; Macroalgae; *Cystoseira*;
38Secondary metabolites.

39Experimental Section

401. *Algal Material*

41 Samples from 15 different species belonging to the Rhodophyta, Chlorophyta and
42Heterokontophyta phyla were collected between July, 2010 and July, 2013 at different locations
43of the Portuguese and Spanish coasts (Table S1). Morphological identification was made by Dr
44Aschwin Engelen, Dr Tânia Pereira and MSc Mafalda Tavares (CCMAR-UAlg), Dr Javier
45Cremades (Facultad de Ciencias, University of A Coruña, Spain) and Dr Ricardo Bermejo
46(University of Cadiz, Spain). Biomass was washed with water to remove epiphytes, before
47freeze-drying, then grounded and stored at -20 °C until use. Vouchers specimens are kept at
48MarBiotech herbarium at the Centre of Marine Sciences, Faro, Portugal.

49

502. *Extracts preparation*

51 Dried biomass was blended with hexane (1:10 w/v) by means of an IKA Ultra-Turrax
52disperser for 1 min for cell wall disruption, and after centrifugation ($5000 \times g$, 10 min) the
53supernatants were recovered. The extraction was repeated three times. The residue was then
54sequentially extracted with CH_2Cl_2 and MeOH in a similar manner. All extracts were evaporated
55under reduced pressure at 40 °C and stored at 4 °C. For the bioactivity assays, extracts were
56dissolved in DMSO (dimethyl sulfoxide) at the concentration of 50 mg/mL.

57

583. *Chemical characterization of Cystoseira extracts*

593.1. *NMR analysis*

60 Hydrogen nuclear magnetic resonance (^1H NMR) spectra were recorded on a Bruker Avance
61III 500 spectrometer, using 5 mm TXI probe, operated at 500.13 MHz for ^1H nucleus.
62Approximately 10 mg of each sample was dissolved in 0.6 mL of CDCl_3 with tetramethylsilane
63(TMS) as a standard reference with a chemical shift $\delta_{\text{H}} = 0.00$ ppm. Spectra were obtained at 25
64°C, with 64 scans, 2 dummy scans, using a 90-degree high power pulse of 8.3 μs , a recycle delay
65of 1s, and 64 K data points covering a spectral width of 7684 Hz. All spectra were processed
66using Topspin 3.2 software.

67

683.2. *GC/FID and GC/LREIMS analysis*

69 Gas chromatography with flame ionization detector (GC/FID) chromatograms were
70 recorded on a Shimadzu GC-2010 gas chromatograph equipped with an FID-detector and an
71 automatic injector (Shimadzu AOC-20i) using a RtX-5 capillary column (5% phenyl, 95%
72 polydimethylsiloxane, 30 m × 0.32 mm × 0.25 µm film thickness; Restek, USA). These analyses
73 were performed by injecting 1.0 µL of a 1.0 mg/mL solution of crude hexane extract in hexane in
74 a split mode (1:30) employing helium as the carrier gas (1 mL/min) under the following
75 conditions: injector and detector temperatures of +270 °C and 300 °C, respectively; oven
76 programmed temperature from 120–290 °C at 8 °C/min, holding 20 min at 290 °C. Gas
77 chromatography–low resolution electron ionization mass spectrometry (GC/LREIMS) analysis
78 was conducted in a Shimadzu GC-17A chromatograph interfaced with a MS-QP-5050A mass
79 spectrometer operating using ionization voltage of 70 eV and an ion source temperature of +350
80 °C with the same conditions described above. Helium was used as the carrier gas.

81

824. *Antileishmanial and cytotoxicity assays*

834.1. *Cytotoxicity against human acute monocytic leukaemia cell line THP-1*

84 Cytotoxicity of all extracts was performed on human acute monocytic leukaemia cell line
85 THP-1 (ATCC TIB-202). Cells were cultivated in RPMI-1640 medium supplemented with 10%
86 heat-inactivated foetal bovine serum (FBS), L-glutamine (2 mM), penicillin (50 U/L) and
87 streptomycin (0.05 mg/L) at 37 °C in humidified atmosphere with 5% CO₂. For the assay, 10⁵
88 THP-1 cells per well were seeded onto the 96-well plates. Extracts were added at concentrations
89 ranging from 4 to 125 µg/mL for 48h, and cell viability was determined by the MTT (3-(4,5-
90 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimetric assay, as described
91 elsewhere (Dutta et al., 2005). Cells used as negative control were treated with DMSO at the
92 highest concentration used in test wells (0.5% v/v). Results were expressed in terms of cell
93 viability (%) and half maximal inhibitory concentration values (IC₅₀ – in µg/mL).

94

954.2. *Antipromastigote assay*

96 Promastigote forms of a *L. infantum* strain (MHOM/PT/88/IMT-151) were obtained from
97 the cryobank of the ‘Instituto de Higiene e Medicina Tropical’ (Universidade Nova de Lisboa,
98 Portugal) and maintained in RPMI-1640 medium supplemented with 10% FBS, L-glutamine,
99 penicillin and streptomycin, at 24 °C. About 2 × 10⁶ parasites per well were incubated in 96-well

100plates with the extracts at concentrations ranging from 4 to 125 µg/mL for 48h. Negative control
101cells were treated with DMSO at the highest concentration used in test wells ($\leq 1\%$ v/v).
102Amphotericin B (0.2 µg/mL), miltefosine (12.7 µg/mL) and pentamidine (0.5 µg/mL) were used
103as positive controls. The effect of the extracts on parasite viability was assessed by the MTT
104colorimetric assay. Results were expressed in terms of cell viability (%) and IC₅₀ values (µg/mL).
105

1064.3. Activity against intracellular amastigotes

107 *L. infantum* intracellular amastigotes (MHOM/MA(BE)/67) were collected from the spleen
108of heavily infected donor hamsters and used to infect primary peritoneal mouse macrophages
109(PMM). PMM (3×10^4 cells per well) were seeded on 96-well plates, and incubated for two days
110for cell attachment. Then, 5×10^5 amastigotes were added to each well (infection ratio about 16
111amastigotes per cell) and infected macrophages were further incubated at 37 °C for 2 h. The
112extracts at concentrations ranging from 0.25 to 64.0 µg/mL were added and the plates were
113further incubated at 37 °C and 5% CO₂. After 5 days, intracellular amastigote burdens were
114microscopically assessed upon Giemsa staining and the inhibitory concentration conferring a
11550% reduction of the intracellular amastigote burden compared to the non-treated infected
116positive controls (CC₅₀) was determined. In addition, cytotoxicity of the extracts was evaluated
117on PMM cells and carried out as previously described (Cos et al., 2016). The reference drug
118(miltefosine) was used as positive control.

119 .

1204.4. Microscopic analysis

121 *Leishmania* promastigotes were incubated with the extracts (125 µg/mL) and with
122amphotericin (0.2 µg/mL) for 48h. After incubation and centrifugation, parasites were smeared
123on microscope slides, fixed with methanol and stained with Giemsa solution and observed using
124a Zeiss AXIOMAGER Z2 microscope, equipped with a cool SNApHQ2 camera and AxioVision
125software version 4.8 (Carl Zeiss MicroImaging GmbH, Göttingen, Germany).

126

1274.5. Apoptosis detection through annexin V-FITC staining

128Promastigotes (4×10^6 /mL) cultured in RPMI medium with DMSO (0.1%) were treated with
129IC₅₀ concentrations of with Cystoseira extracts at IC₅₀ concentrations for 48h. Negative and
130positive controls cells were treated with DMSO at the highest concentration used in test wells (\leq

1311% v/v) and amphotericin B (0.6 µg/mL), respectively. Apoptotic effect of the tested extracts on
132*L. infantum* promastigotes was evaluated by flow cytometry using the Annexin V-FITC
133(fluorescein isothiocyanate) Apoptosis Kit - KA0714 (Abnova) in accordance with the
134manufacturer's recommendations. Briefly, treated and control promastigotes were washed with
135culture medium and resuspended in 500 µL binding buffer and stained with 5 µL of annexin V-
136FITC (10 mg/mL) and 5 µL of propidium iodide (PI; 50µg/ml) and incubate at room temperature
137for 5 min in the dark. Results were obtained by flow cytometry using a FACS Calibur Flow
138Cytometer (Becton-Dickinson, East Rutherford, NJ, USA) using the Cell Quest software (BD
139Biosciences, San Jose, CA, USA) for acquisition and result analysis. Ten thousand events were
140analysed and apoptosis evaluated based on the geometric mean of the fluorescence intensity
141detected in channels 1 (for annexin) and 2 (for PI) (Farias et al., 2013).

142

1436. *Statistical analysis*

144 The antileishmanial and cytotoxic assays were conducted in triplicate and the results were
145expressed as mean and standard error of the mean (SEM). The IC₅₀ values were calculated using
146sigmoid regression on the logarithm of the concentration-response data in the GraphPad Prism V
1475.0 software. Student's t-test was used to determine whether differences between means were
148significant at different levels ($p < 0.05$ and $p < 0.01$).

149

150References

151Dutta A, Bandyopadhyayb S, Mandala C, Chatterjeeb M. 2005. Development of a modified
152MTT assay for screening antimonial resistant field isolates of Indian visceral leishmaniasis.
153*Parasitol. Int.* 54:119-122.

154Cos P, Vlietinck AJ, Vanden Berghe D, Maes L. 2016. Anti-infective potential of natural
155products: how to develop a stronger *in vitro* proof-of-concept. *J. Ethnopharmacol.* 106:290-302.

156Farias LH, Rodrigues AP, Silveira FT, Seabra SH, DaMatta RA, Saraiva EM, Silva EO. 2013.
157Phosphatidylserine exposure and surface sugars in two *Leishmania (Viannia) braziliensis* strains
158involved in cutaneous and mucocutaneous leishmaniasis. *J. Infect. Dis.* 207(3):537-43.

161Table S1. Species, date of collection and collection site of the macroalgae used in this study

Phylum /Species	Date	Local	Country
Chlorophyta			
<i>Cladophora albida</i> (Nees) Kützing	July 2010	Olhos de Água ¹	Portugal
<i>Codium</i> sp. Stackhouse	July 2010	Olhos de Água ¹	Portugal
Heterokontophyta			
<i>Cladostephus spongiosus</i> (Hudson) C. Agardh	July 2010	Olhos de Água ¹	Portugal
<i>Cystoseira baccata</i> (S. G. Gmelin) P. C. Silva	July 2012	Areosa ²	Portugal
<i>Cystoseira barbata</i> (Stackhouse) C. Agardh	March 2013	Cadiz Bay ¹	Spain
<i>Cystoseira humilis</i> Schousboe ex Kützing	May 2012	Almograve ³	Portugal
<i>Cystoseira nodicaulis</i> (Withering) M. Roberts	April 2013	Santa Mariña ²	Spain
<i>Cystoseira tamariscifolia</i> (Hudson) Papenfuss	July 2012	Areosa ²	Portugal
<i>Cystoseira usneoides</i> (L.) M. Roberts	September 2012	Olhos de Água ¹	Portugal
<i>Halopteris scoparia</i> (L.) Sauvageau	July 2010	Olhos de Água ¹	Portugal
<i>Sargassum muticum</i> (Yendo) Fensholt	July 2010	Olhos de Água ¹	Portugal
<i>Taonia atomaria</i> (Woodward) J. Agardh	July 2010	Olhos de Água ¹	Portugal
Rhodophyta			
<i>Peyssonnelia squamaria</i> (S. G. Gmelin) Decaisne	July 2013	Arrifes ¹	Portugal
<i>Plocamium cartilagineum</i> (L.) P. S. Dixon	July 2012	Olhos de Água ¹	Portugal
<i>Scinaia furcellata</i> (Turner) J. Agardh	July 2013	Olhos de Água ¹	Portugal

¹Southern coast, ²Northwestern coast and ³Southwestern coast of the Iberian Peninsula.

164**Table S2. Inhibitory concentrations of algal extracts against *L. infantum* and mammalian**
165**cells**

Species	Extract/ Compound	IC ₅₀ (µg/mL) ^a Promastigotes	CC ₅₀ (µg/mL) ^b Amastigotes	IC ₅₀ (µg/mL) ^a THP-1
<i>Cladophora albida</i>	Hexane	>125	-	>125
	CH ₂ Cl ₂	>125	-	>125
	MeOH	>125	-	>125
<i>Cladostephus spongiosus</i>	Hexane	>125	-	>125
	CH ₂ Cl ₂	>125	-	>125
	MeOH	>125	-	>125
<i>Cystoseira baccata</i>	Hexane	94.1 ± 1.5	5.1 ± 0.0	>125
	CH ₂ Cl ₂	>125	-	76.2 ± 3.9
	MeOH	>125	-	>125
<i>Cystoseira barbata</i>	Hexane	78.7 ± 3.2	6.8 ± 0.0	79.5 ± 2.3
	CH ₂ Cl ₂	>125	-	>125
	MeOH	>125	-	>125
<i>Cystoseira humilis</i>	Hexane	>125	-	>125
	CH ₂ Cl ₂	>125	-	>125
	MeOH	>125	-	>125
<i>Cystoseira tamariscifolia</i>	Hexane	31.2 ± 0.9	-	30.9 ± 0.4
	CH ₂ Cl ₂	29.8 ± 0.5	-	19.9 ± 0.5
	MeOH	>125	-	>125
<i>Cystoseira nodicaulis</i>	Hexane	>125	-	>125
	CH ₂ Cl ₂	>125	-	>125
	MeOH	>125	-	>125
<i>Cystoseira usneoides</i>	Hexane	59.9 ± 0.2	-	16.6 ± 0.3
	CH ₂ Cl ₂	33.6 ± 0.6	-	12.6 ± 0.4
	MeOH	>125	-	45.0 ± 0.4
<i>Codium sp.</i>	Hexane	>125	-	>125
	CH ₂ Cl ₂	>125	-	>125
	MeOH	>125	-	>125
<i>Dictyota spiralis</i>	Hexane	48.3 ± 0.7	-	-
	CH ₂ Cl ₂	>125	-	-
	MeOH	>125	-	-
<i>Halopteris scoparia</i>	Hexane	>125	-	>125
	CH ₂ Cl ₂	>125	-	>125
	MeOH	>125	-	>125
<i>Peysonnelia squamaria</i>	Hexane	>125	-	>125
	CH ₂ Cl ₂	>125	-	>125
	MeOH	>125	-	>125
<i>Plocamium cartilagineo</i>	Hexane	101.8±2.8	-	51.6±0.1
	CH ₂ Cl ₂	>125	-	>125
	MeOH	>125	-	>125
<i>Sargassum muticum</i>	Hexane	>125	-	>125
	CH ₂ Cl ₂	>125	-	>125
	MeOH	>125	-	>125
<i>Scinaria funcellata</i>	Hexane	>125	-	>125
	CH ₂ Cl ₂	>125	-	>125
	MeOH	>125	-	>125


Species	Extract/ Compound	IC ₅₀ (µg/mL) ^a Promastigotes	CC ₅₀ (µg/mL) ^b Amastigotes	IC ₅₀ (µg/mL) ^a THP-1
<i>Taonia atomaria</i>	Hexane	>125	-	>125
	CH ₂ Cl ₂	>125	-	>125
	MeOH	>125	-	>125
Positive controls	Miltefosine	12.7 ± 1.8	8.8 ± 0.0	8.8 ± 0.0
	Amphotericin	0.2 ± 0.0	-	-
	Pentamidine	0.5 ± 0.1	-	-

^aIC₅₀ - Inhibitory concentration of extract / compound causing 50% reduction of the promastigote and human acute monocytic leukaemia cell line THP-1 cells growth; ^bCC₅₀ - Inhibitory concentration of extract / compound causing 50% reduction of the intracellular amastigote burden compared to the non-treated infected controls. IC₅₀ and CC₅₀ values represent the mean ± standard error of the mean of three experiments performed in triplicate.

167**Table S3. Class of metabolites found in *Cystoseira* extracts**

Species	Extracts	Class of metabolites ¹
<i>C. baccata</i>	Hexane	FA, TAG, CAR, ST
	CH ₂ Cl ₂	MT, FA
	MeOH	MT
<i>C. barbata</i>	Hexane	FA, TAG, CAR, ST
	CH ₂ Cl ₂	MT, FA
	MeOH	MT
<i>C. humilis</i>	Hexane	FA, TAG, CAR
	CH ₂ Cl ₂	FA
	MeOH	FA, MT
<i>C. nodicaulis</i>	Hexane	FA, TAG, CAR, ST
	CH ₂ Cl ₂	MT, FA
	MeOH	FA
<i>C. tamariscifolia</i>	Hexane	FA, TAG, CAR
	CH ₂ Cl ₂	MT, FA
	MeOH	MT
<i>C. usneoides</i>	Hexane	MT, FA
	CH ₂ Cl ₂	MT, FA
	MeOH	MT


¹FA - fatty acids, TAG - triacylglycerols, CAR - carotenoids, ST - steroids, MT - meroterpenoids




169

170**Figure S1.** Effect of *C. nodicaulis* and *C. barbata* hexane extracts (125 µg/mL, 48h) on the
171morphology of *L. infantum* promastigotes. Control cells cultured in RPMI medium alone (**A**)
172treated with the control drug amphotericin B (0.2 µg/mL; **B**), and treated with *C. nodicaulis* (**C**)
173or *C. barbata* (**D**) extracts. Bright field images; the scale bar corresponds to 5 µm.

174



175
 176 **Figure S2.** ^1H NMR spectra (500 MHz, CDCl_3) of the *Cystoseira baccata* (A), *C. barbata* (B).
 177 *tamariscifolia* (C) and *C. usneoides* (D) hexane extracts.



178
 179 **Figure S3.** ^1H NMR spectra (500 MHz, CDCl_3) of the *Cystoseira. baccata* (**A**), *C. barbata* (**B**),
 180 *C. tamariscifolia* (**C**) and *C. usneoides* (**D**) CH_2Cl_2 extracts.

181

182